Why Did Buffett Sell the S&P 500?
Warren Buffett has always been an advocate of investing in…
Sell
2
CRON Quote, Financials, Valuation and Earnings
Last price:
$1.80
Seasonality move
:
-11.8%
Day range:
$1.77 - $1.84
52-week range:
$1.77 - $3.14
Dividend yield:
0%
P/E ratio:
16.27x
P/S ratio:
5.83x
P/B ratio:
0.64x
Volume:
937.5K
Avg. volume:
1.5M
1-year change:
-31.42%
Market cap:
$684.7M
Revenue:
$117.6M
EPS (TTM):
$0.11
Analysts' Opinion
-
Consensus RatingCronos Group has received a consensus rating of Hold. The company's average rating is a Hold based on 1 Buy rating, 2 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $2.06, Cronos Group has an estimated upside of 15.09% from its current price of $1.79.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $2.01 representing 100% downside risk from its current price of $1.79.
Fair Value
-
According to the consensus of 3 analysts, Cronos Group has 15.09% upside to fair value with a price target of $2.06 per share.
CRON vs. S&P 500
-
Over the past 5 trading days, Cronos Group has overperformed the S&P 500 by 1.55% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Cronos Group does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Cronos Group has grown year-over-year revenues for 6 quarters straight. In the most recent quarter Cronos Group reported revenues of $30.3M.
Earnings Growth
-
Cronos Group has grown year-over-year earnings for 1 quarter straight. In the most recent quarter Cronos Group reported earnings per share of $0.12.
Enterprise value:
-127.2M
EV / Invested capital:
--
Price / LTM sales:
5.83x
EV / EBIT:
--
EV / Revenue:
-1.08x
PEG ratio (5yr expected):
--
EV / Free cash flow:
-22.35x
Price / Operating cash flow:
120.50x
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$25.2M
Return On Assets:
3.61%
Net Income Margin (TTM):
34.93%
Return On Equity:
3.76%
Return On Invested Capital:
3.76%
Operating Margin:
-37.51%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Income Statement | ||||||
| Revenue | $89.1M | $87.2M | $117.6M | $23.9M | $30.3M | |
| Gross Profit | $15.7M | $11.9M | $25.2M | $1.9M | $10.8M | |
| Operating Income | -$107.6M | -$79.9M | -$59.5M | -$18.2M | -$11.4M | |
| EBITDA | -$94.5M | -$71.8M | -$50.2M | -$17M | -$8.8M | |
| Diluted EPS | -$0.45 | -$0.18 | $0.11 | -$0.11 | $0.12 | |
| Period Ending | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $1.4B | $1.1B | $960.2M | $933.3M | $936.1M | |
| Total Assets | $1.9B | $1.4B | $1.2B | $1.1B | $1.2B | |
| Current Liabilities | $206.8M | $54.4M | $68.1M | $41.4M | $49.7M | |
| Total Liabilities | $217.5M | $63.5M | $72M | $44.1M | $55.3M | |
| Total Equity | $1.7B | $1.3B | $1.1B | $1.1B | $1.1B | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$88.9M | -$42.8M | $18.8M | $16.8M | $7.7M | |
| Cash From Investing | -$1.8M | -$59.5M | $175.1M | $81.9M | -$5M | |
| Cash From Financing | -$2.9M | -$1M | -$1.2M | -$218K | -$313K | |
| Free Cash Flow | -$94M | -$46.3M | $5.7M | $15M | $4M | |
CRON
Sector
Market Cap
$684.7M
$36.5M
Price % of 52-Week High
57.01%
44.66%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.9%
1-Year Price Total Return
-31.42%
-39.9%
Beta (5-Year)
0.895
0.774
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$1.82
200-day SMA
Sell
Level
$2.13
Bollinger Bands (100)
Sell
Level
1.89 - 2.07
Chaikin Money Flow
Sell
Level
-952.9K
20-day SMA
Sell
Level
$1.90
Relative Strength Index (RSI14)
Sell
Level
40.12
ADX Line
Sell
Level
18.31
Williams %R
Buy
Level
-88.2353
50-day SMA
Sell
Level
$1.92
MACD (12, 26)
Buy
Level
0.50
25-day Aroon Oscillator
Sell
Level
-80
On Balance Volume
Sell
Level
-3.1M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (9.7731)
Buy
CA Score
(Annual)
Level (1.3525)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (4)
Buy
Ohlson Score
Level (-6.2711)
Buy
Piotroski F Score
(Annual)
Level (6)
Sell
Quality Ratio Score
Level (1)
Buy
Fundamental Score
Level (5)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Cronos Group, headquartered in Toronto, Canada, cultivates and sells medicinal and recreational cannabis through its medicinal brand, Peace Naturals, and its two recreational brands, Cove and Spinach. Although it primarily operates in Canada, Cronos exports medical cannabis primarily to Israel. In the US, the company has an option to acquire 5.9% of US multistate operator PharmaCann on a fully diluted basis upon easing of federal prohibition.
Stock Forecast FAQ
In the current month, CRON has received 1 Buy ratings 2 Hold ratings, and 0 Sell ratings. The CRON average analyst price target in the past 3 months is $2.06.
-
Where Will Cronos Group Stock Be In 1 Year?
According to analysts, the consensus estimate is that Cronos Group share price will rise to $2.06 per share over the next 12 months.
-
What Do Analysts Say About Cronos Group?
Analysts are divided on their view about Cronos Group share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Cronos Group is a Sell and believe this share price will drop from its current level to $2.01.
-
What Is Cronos Group's Price Target?
The price target for Cronos Group over the next 1-year time period is forecast to be $2.06 according to 3 Wall Street analysts, 1 of them rates the stock a Buy, 0 rate the stock a Sell, and 2 analysts rate the stock a Hold.
-
Is CRON A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Cronos Group is a Hold. 2 of 3 analysts rate the stock a Hold at this time.
-
How Can I Buy Shares Of CRON?
You can purchase shares of Cronos Group via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Cronos Group shares.
-
What Is The Cronos Group Share Price Today?
Cronos Group was last trading at $1.80 per share. This represents the most recent stock quote for Cronos Group. Yesterday, Cronos Group closed at $1.79 per share.
-
How To Buy Cronos Group Stock Online?
In order to purchase Cronos Group stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will SoundHound AI Stock Recover?
SoundHound AI (NASDAQ:SOUN) is a leading maker of artificial intelligence…
What Stocks Did Warren Buffett Just Buy?
In Q4 of last year, Warren Buffett added to or…
Stock Ideas
Buy
53
Is AAPL Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 36x
Sell
46
Is MSFT Stock a Buy?
Market Cap: $2.8T
P/E Ratio: 32x
Sell
41
Is NVDA Stock a Buy?
Market Cap: $2.7T
P/E Ratio: 37x
Alerts
Buy
78
AJINY alert for Mar 29
Ajinomoto [AJINY] is up 99.61% over the past day.
Buy
69
AGX alert for Mar 29
Argan [AGX] is up 19.83% over the past day.
Sell
24
AIR alert for Mar 29
AAR [AIR] is down 16.36% over the past day.
